Alnylam Pharmaceuticals (ALNY) to Release Earnings on Thursday

Alnylam Pharmaceuticals (NASDAQ:ALNY) is expected to release its Q4 2025 results before the market opens on Thursday, February 12th. Analysts expect Alnylam Pharmaceuticals to post earnings of $1.43 per share and revenue of $1.1574 billion for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, February 12, 2026 at 8:30 AM ET.

Alnylam Pharmaceuticals Stock Up 0.0%

Shares of NASDAQ:ALNY opened at $351.96 on Thursday. The company’s fifty day moving average is $394.28 and its two-hundred day moving average is $424.94. The company has a debt-to-equity ratio of 4.45, a quick ratio of 2.49 and a current ratio of 2.54. Alnylam Pharmaceuticals has a 1-year low of $205.87 and a 1-year high of $495.55. The stock has a market capitalization of $46.50 billion, a price-to-earnings ratio of 1,466.50 and a beta of 0.35.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on ALNY shares. Leerink Partners dropped their price objective on shares of Alnylam Pharmaceuticals from $370.00 to $351.00 and set a “market perform” rating on the stock in a research note on Monday, December 15th. Bank of America dropped their price target on Alnylam Pharmaceuticals from $529.00 to $462.00 and set a “buy” rating on the stock in a research report on Friday, January 30th. Stifel Nicolaus raised their price target on Alnylam Pharmaceuticals from $495.00 to $508.00 and gave the stock a “buy” rating in a report on Thursday, December 11th. Wall Street Zen upgraded Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Monday, November 10th. Finally, Wells Fargo & Company dropped their target price on Alnylam Pharmaceuticals from $479.00 to $376.00 and set an “equal weight” rating on the stock in a research report on Tuesday, January 20th. Twenty-two research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $477.13.

Insider Activity at Alnylam Pharmaceuticals

In related news, CEO Yvonne Greenstreet sold 15,650 shares of the company’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $453.69, for a total value of $7,100,248.50. Following the completion of the sale, the chief executive officer owned 65,409 shares of the company’s stock, valued at $29,675,409.21. This represents a 19.31% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Kevin Joseph Fitzgerald sold 12,128 shares of the firm’s stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $452.18, for a total transaction of $5,484,039.04. Following the transaction, the executive vice president directly owned 21,264 shares in the company, valued at approximately $9,615,155.52. The trade was a 36.32% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 56,955 shares of company stock worth $24,072,733 in the last ninety days. 1.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in ALNY. Caitong International Asset Management Co. Ltd acquired a new stake in Alnylam Pharmaceuticals in the third quarter worth approximately $29,000. Newbridge Financial Services Group Inc. acquired a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at $39,000. Geneos Wealth Management Inc. raised its stake in shares of Alnylam Pharmaceuticals by 372.3% in the 1st quarter. Geneos Wealth Management Inc. now owns 222 shares of the biopharmaceutical company’s stock worth $60,000 after buying an additional 175 shares in the last quarter. Larson Financial Group LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 35.1% in the third quarter. Larson Financial Group LLC now owns 300 shares of the biopharmaceutical company’s stock valued at $137,000 after buying an additional 78 shares during the period. Finally, Horizon Investments LLC boosted its stake in Alnylam Pharmaceuticals by 18.5% during the third quarter. Horizon Investments LLC now owns 403 shares of the biopharmaceutical company’s stock valued at $184,000 after buying an additional 63 shares in the last quarter. 92.97% of the stock is currently owned by institutional investors.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.